Terms: = Gastric cancer AND PR, PGR, progesterone receptor AND Treatment
453 results:
1. ApoA-I and ApoB levels, and ApoB-to-ApoA-I ratio as candidate pre-treatment biomarkers of pathomorphological response to neoadjuvant therapy in gastric and esophago-gastric junction adenocarcinoma.
Nurczyk K; Nowak N; Orczykowski T; Bojar P; Duma D; Gieroba R; Wallner G; Skoczylas T
Pol Przegl Chir; 2023 Sep; 96(2):44-49. PubMed ID: 38629280
[TBL] [Abstract] [Full Text] [Related]
2. Clinical evidence for efficacy of pembrolizumab in MSI-H and TMB-H advanced solid tumor: results from three cancer centers in China.
Yan H; Song L; Li Y; Xu Q; Guo W; Lin S; Jiang W; Wang Z; Deng L; Huang Z; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zhang Y; Zeng L
Cancer Immunol Immunother; 2024 Mar; 73(4):74. PubMed ID: 38451314
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
4. [A Case of HER2-Positive Unresectable Advanced gastric cancer Showing Long-Term Complete Response Treated by Only Chemotherapy].
Shirasaki Y; Wada N; Takachi K; Fujiwara M; Fukuda N; Matsuura Y; Munakata K; Takiuchi D; Hama N; Ota H
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1887-1888. PubMed ID: 38303241
[TBL] [Abstract] [Full Text] [Related]
5. [A Case of Recurrent gastric cancer with Long-Term Control via Two Resections and Multidisciplinary treatment Including Nivolumab].
Bungo M; Takeno A; Hirao M; Hamakawa T; Yamamoto M; Matsui Y; Tokuyama S; Toshiyama R; Kawai K; Takahashi Y; Sakai K; Doi T; Goto K; Kato T; Takami K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1715-1717. PubMed ID: 38303183
[TBL] [Abstract] [Full Text] [Related]
6. [Conversion Surgery Performed after SOX plus Nivolumab Therapy for Advanced gastric cancer with Para-Aortic Lymph Node Metastasis].
Okuda T; Odagiri K; Yanagimoto Y; Yamashita M; Takeyama H; Suzuki Y; Ikenaga M; Kawase T; Shimizu J; Imamura H; Dono K
Gan To Kagaku Ryoho; 2023 Dec; 50(13):1671-1673. PubMed ID: 38303168
[TBL] [Abstract] [Full Text] [Related]
7. [A Case of Long-Term Survival without Recurrence after Completion of Immunotherapy Due to Response of Third- Line Nivolumab for Liver Metastasis Recurrence of Esophagogastric Junction cancer].
Ryuzaki T; Sentsui T; Amagai H; Sasagawa S; Kobayashi S; Tsukamoto S; Koide Y; Matsubara H
Gan To Kagaku Ryoho; 2023 Oct; 50(10):1126-1129. PubMed ID: 38035852
[TBL] [Abstract] [Full Text] [Related]
8. Patterns of Recurrence After Poor Response to Neoadjuvant Chemotherapy in gastric cancer and the Role for Adjuvant Radiation.
Hui C; Ewongwo A; Lau B; Fisher G; Delitto D; Poultsides G; Ho QA; Rahimy E; Pollom E; Chang DT; Vitzthum LK
Ann Surg Oncol; 2024 Jan; 31(1):413-420. PubMed ID: 37755563
[TBL] [Abstract] [Full Text] [Related]
9. Perspectives for immunotherapy of EBV-associated GLELC: A relatively "hot" tumor microenvironment.
Lei Y; Cao P; Zheng X; Wei J; Cheng M; Liu M
Cancer Med; 2023 Oct; 12(19):19838-19849. PubMed ID: 37732493
[TBL] [Abstract] [Full Text] [Related]
10. Stent Graft of Pseudoaneurysm Rupture After Subtotal Stomach-preserving Pancreaticoduodenectomy.
Kimura K; Minagawa R; Yamaoka T; Izumi T; Takahashi YU; Nakanishi M; Tokunaga T; Matsuda D; Honma K; Nagata S; Minami K; Nishizaki T
Anticancer Res; 2023 Aug; 43(8):3639-3645. PubMed ID: 37500164
[TBL] [Abstract] [Full Text] [Related]
11. Noninvasive imaging evaluation of peritoneal recurrence and chemotherapy benefit in gastric cancer after gastrectomy: a multicenter study.
Sun Z; Wang W; Huang W; Zhang T; Chen C; Yuan Q; Chen Y; Zhou K; Han Z; Feng H; Chen H; Liang X; Hu Y; Yu J; Liu H; Yu L; Xu Y; Li G; Jiang Y
Int J Surg; 2023 Jul; 109(7):2010-2024. PubMed ID: 37300884
[TBL] [Abstract] [Full Text] [Related]
12. Calcium electroporation in cutaneous metastases - A non-randomised phase II multicentre clinical trial.
Vissing M; Pervan M; Pløen J; Schnefeldt M; Rafaelsen SR; Jensen LH; Rody A; Gehl J
Eur J Surg Oncol; 2023 Sep; 49(9):106925. PubMed ID: 37268521
[TBL] [Abstract] [Full Text] [Related]
13. A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study.
Gravis G; Marino P; Olive D; Penault-LLorca F; Delord JP; Simon C; Lamrani-Ghaouti A; Sabatier R; Ciccolini J; Boher JM
BMC Cancer; 2023 May; 23(1):393. PubMed ID: 37131154
[TBL] [Abstract] [Full Text] [Related]
14. Analysis of the efficacy and influencing factors of preoperative P-SOX neoadjuvant chemotherapy regimen for progressive gastric cancer-construction of a clinical prediction model.
Feng L; Shao L; Sun S; Zhang C; Cai B
Cancer Med; 2023 Jun; 12(12):13031-13040. PubMed ID: 37096925
[TBL] [Abstract] [Full Text] [Related]
15. Clinicopathological Features and Prognosis of Gastrointestinal Metastases From Breast Carcinoma: A Clinicopathological Study of 22 Patients.
Wang S; Li W; Li S; Liu X; Zhang L; Hao C; Meng W; Zhao W; Tong Z
Int J Surg Pathol; 2023 Sep; 31(6):1075-1084. PubMed ID: 36803140
[No Abstract] [Full Text] [Related]
16. [Combined Modality Therapy for HER2-Positive Progressive Stomach cancer Metastasis Achieving treatment Response-A Case Report].
Kosaka A; Miyoshi K; Kaneko Y; Matsumoto M; Tsurui K; Enomoto M; Iwasaki K; Ota Y; Katsumata K; Nagakawa Y
Gan To Kagaku Ryoho; 2022 Dec; 49(13):1902-1904. PubMed ID: 36733038
[TBL] [Abstract] [Full Text] [Related]
17. Risk model and factors for prediction of response to neoadjuvant chemotherapy in patients with advanced gastric cancer-a two-center cohort study.
Liang XW; Xiao WS; Lei H; Huag QC; Dong YL; Wang F; Qing WP
BMC Cancer; 2023 Jan; 23(1):41. PubMed ID: 36631788
[TBL] [Abstract] [Full Text] [Related]
18. Patients with positive HER-2 amplification advanced gastroesophageal junction cancer achieved complete response with combined chemotherapy of AK104/cadonilimab (PD-1/CTLA-4 bispecific): A case report.
Peng J; Zhu Q; Peng Z; Chen Z; Liu Y; Liu B
Front Immunol; 2022; 13():1049518. PubMed ID: 36569905
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of copanlisib in relapsed/refractory B-cell non-Hodgkin lymphoma: A meta-analysis of prospective clinical trials.
Wang J; Zhou H; Mu M; Zhao A; Cai Z; Li L; Wang M; Niu T
Front Immunol; 2022; 13():1034253. PubMed ID: 36439091
[TBL] [Abstract] [Full Text] [Related]
20. First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O; Chiappori AA; Thompson JA; Doi T; Hu-Lieskovan S; Eskens FALM; Ros W; Diab A; Spano JP; Rizvi NA; Wasser JS; Angevin E; Ott PA; Forgie A; Yang W; Guo C; Chou J; El-Khoueiry AB
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36302562
[TBL] [Abstract] [Full Text] [Related]
[Next]
